Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

Spugnini, Enrico P.; Crispi, Stefania; Scarabello, Alessandra; Caruso, Giovanni; Citro, Gennaro; Baldi, Alfonso

doi:10.1186/1756-9966-27-6

Cited by 39 publications

(33 citation statements)

References 27 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data support previous observations [ 30 , 42 , 43 ] of a synergistic effect of piroxicam, when used in combination with CDDP on cell cycle regulation and apoptosis. Interestingly, the specific check-points affected by this treatment are not overlapping in different cell lines, this demonstrating that the effects of piroxicam could be on multiple targets.…”

Section: Discussionsupporting

confidence: 92%

RETRACTED ARTICLE: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

Verdina¹,

Cardillo²,

Nebbioso

et al. 2008

J Transl Med

Self Cite

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed for prevention and treatment of a variety of human cancers. Piroxicam, in particular, has been recently shown to exert significant anti-tumoral activity in combination with cisplatin (CDDP) on mesothelioma cells. However, the mechanisms through which NSAIDs regulate the cell cycle as well as the signal pathways involved in the growth inhibition, remain unclear. In the present study, using two mesothelioma cell lines, MSTO-211H and NCI-H2452, we have investigated the influence of piroxicam alone and in association with CDDP on proliferation, cell cycle regulation and apoptosis. In both cell lines a significant effect on cell growth inhibition, respect to the control, was observed with all the drugs tested. Moreover, treatment with piroxicam or CDDP alone altered the cell cycle phase distribution as well as the expression of some cell cycle regulatory proteins in both cell lines. These effects were increased, even if in a not completely overlapping manner, after treatment with the association of piroxicam and CDDP. In particular, the two drugs in NCI cell line had a synergistic effect on apoptosis, probably through activation of caspase 8 and caspase 9, while the most evident targets among the cell cycle regulators were cyclin D1 and p21 waf1 . These results suggest that the association of piroxicam and CDDP specifically triggers cell cycle regulation and apoptosis in different mesothelioma cell lines and may hold promise in the treatment of mesothelioma.

show abstract

Section: Discussionsupporting

confidence: 92%

RETRACTED ARTICLE: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

Verdina¹,

Cardillo²,

Nebbioso

et al. 2008

J Transl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results were confirmed in vivo , in a mouse MM model indicating that piroxicam and cisplatin association specifically acts on cell cycle regulation triggering apoptosis, and may hold promise in the treatment of MM [11]. Finally in spontaneous MM in pets, we recently have been able to show that piroxicam/cisplatin combination has remarkable efficacy at controlling the malignant effusion secondary to MM in our samples [18].…”

Section: Introductionsupporting

confidence: 70%

Apoptosis Induced by Piroxicam plus Cisplatin Combined Treatment Is Triggered by p21 in Mesothelioma

et al. 2011

Self Cite

View full text Add to dashboard Cite

BackgroundMalignant mesothelioma (MM) is a rare, highly aggressive tumor, associated to asbestos exposure. To date no chemotherapy regimen for MM has proven to be definitively curative, and new therapies for MM treatment need to be developed. We have previously shown in vivo that piroxicam/cisplatin combined treatment in MM, specifically acts on cell cycle regulation triggering apoptosis, with survival increase.Methodology/Principal FindingsWe analyzed, at molecular level, the apoptotic increase caused by piroxicam/cisplatin treatment in MM cell lines. By means of genome wide analyses, we analyzed transcriptional gene deregulation both after the single piroxicam or cisplatin and the combined treatment. Here we show that apoptotic increase following combined treatment is mediated by p21, since apoptotic increase in piroxicam/cisplatin combined treatment is abolished upon p21 silencing.Conclusions/SignificancePiroxicam/cisplatin combined treatment determines an apoptosis increase in MM cells, which is dependent on the p21 expression. The results provided suggest that piroxicam/cisplatin combination might be tested in clinical settings in tumor specimens that express p21.

show abstract

“…Intravenous carboplatin use in cats is less frequently reported; however, reported uses include extraskeletal osteosarcoma (Spugnini and others 2001, Dhaliwal and others 2003) and a variety of sarcomas and carcinomas (Kisseberth and others 2008). Carboplatin has also been reported to be administered by intracavitary injection for mesothelioma in dogs and cats (Spugnini and others 2008) and intralesional injection for feline squamous cell carcinoma (Theon and others 1996).…”

Section: Introductionmentioning

confidence: 99%

Owner's perception of carboplatin in conjunction with other palliative treatments for cancer therapy

Bowles¹,

Galloway²,

Walker

2010

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives: To determine owner's perception of their pet's quality of life during treatment with carboplatin for a variety of canine and feline neoplasms. Methods: Owners were contacted via a postal questionnaire and asked questions regarding their perception of chemotherapy in pets and their perception of carboplatin treatment in their pet. Results: Twenty‐eight (59%) of owners responded to the questionnaire. Forty‐three percent of owners had not considered chemotherapy in pets before treatment; however, after treatment, 89% of owners supported its use. Sixteen (57%) patients had mild to severe side effects. Most patients experienced mild side effects, including lethargy and loss of appetite. Quality of life during treatment was reduced compared with prediagnosis quality of life however at its best was significantly improved compared with pretreatment quality of life. Eighty‐nine per cent of respondents did not regret treating their pet. Clinical Significance: Carboplatin is well tolerated by both owners and pets. Most patients have either no side effects or experience mild lethargy or inappetence. Carboplatin treatment, either alone or in conjunction with other medications, should be considered as a palliative treatment in both dogs and cats with susceptible neoplasms.

show abstract

Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations

Cited by 39 publications

References 27 publications

RETRACTED ARTICLE: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

RETRACTED ARTICLE: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

Apoptosis Induced by Piroxicam plus Cisplatin Combined Treatment Is Triggered by p21 in Mesothelioma

Owner's perception of carboplatin in conjunction with other palliative treatments for cancer therapy

Contact Info

Product

Resources

About